Comparing treatments for painful irreversible pulpitis in mature teeth
A-prf,Nanochitosan Combined With A-prf Scaffold Compared to Chitosan in Vital Pulp Therapy for Symptomatic Irreversible Pulpitis of Mature Permanent Mandibular First Molar Teeth .Randomized Controlled Trials
NA · Future University in Egypt · NCT06438523
This study is testing different treatments for painful irreversible pulpitis in adult molars to see which one helps reduce pain and improve healing the best.
Quick facts
| Phase | NA |
|---|---|
| Study type | Interventional |
| Enrollment | 30 (estimated) |
| Ages | 15 Years to 30 Years |
| Sex | All |
| Sponsor | Future University in Egypt (other) |
| Locations | 1 site (Cairo, Fifth Settlement) |
| Trial ID | NCT06438523 on ClinicalTrials.gov |
What this trial studies
This clinical trial evaluates the effectiveness of A-prf and A-prf combined with nanochitosan compared to chitosan in treating symptomatic irreversible pulpitis in lower permanent first molars. Participants will be divided into three groups, each receiving a different treatment approach. The study will assess tooth sensitivity, radiographic changes, and pain levels over a week following pulpotomy. The goal is to determine which treatment provides better outcomes for patients suffering from this dental condition.
Who should consider this trial
Good fit: Ideal candidates are patients aged 15-30 with symptomatic irreversible pulpitis in mature mandibular molars.
Not a fit: Patients with immature roots or systemic diseases affecting healing may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved treatment options for patients with irreversible pulpitis, potentially reducing pain and enhancing healing.
How similar studies have performed: While there is ongoing research in dental treatments for pulpitis, the specific combination of A-prf and nanochitosan is relatively novel and has not been extensively tested in prior studies.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients suffering from Symptomatic irreversible pulpitis in mature mandibular molars only will be involved. * Patients of either gender aged from 15-30. * Tooth should give positive response to cold test. * Haemostasias should be achieved after total pulpotomy. * The tooth is restorable and free from advanced periodontal disease, cracks and splits. * Patients should be free from any systemic disease that may affect normal healing and predictable outcome. * Patients who will agree to the consent and will commit to follow-up period. * Patients with mature root. * Patients with no internal or external resorption and no periapical lesions. * Soft tissues around the tooth are normal with no swelling or sinus tract. Exclusion Criteria: * Patients with immature roots. * Haemostasias after 10 minutes can not be controlled after total pulpotomy * Patients with any systemic disease that may affect normal healing. * Patients with periapical lesions or infections. * Pregnant females. * Patients who could/would not participate in a 6 months follow-up. * Patients with fistula or swelling * Patients with necrotic pulp. * Patients with old age.
Where this trial is running
Cairo, Fifth Settlement
- Future university — Cairo, Fifth Settlement, Egypt (RECRUITING)
Study contacts
- Principal investigator: Hani s sadek, Prof. — Future University in Egypt
- Study coordinator: mai S abdelwahed, Bachelor
- Email: memo_141997@HOTMAIL.COM
- Phone: 01068609957
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Pulpitis - Irreversible